slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 75,721-75,750
Pages 3,679
Rows per page 30
Component
75,721-75,750 of 110,355
11
The table provides a reconciliation of GAAP guidance to adjusted figures for the three months ending March 31, 2024.Electronic Arts | Results Presentation Deck | 17 slides · Electronic Arts
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
12
The table reconciles GAAP guidance ranges with specific non-GAAP adjustments.Electronic Arts | Results Presentation Deck | 17 slides · Electronic Arts
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
14
The slide provides specific FX rate assumptions for EUR, GBP, CAD, and SEK for Q3 2023, Q3 2024, and Q4E 2024, along with sensitivity analysis for a 10% USD strengthening.Electronic Arts | Results Presentation Deck | 17 slides · Electronic Arts
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
15
The slide presents two separate tables: one for Q4 and one for the full year, detailing the impact of currency on year-over-year growth rates.Electronic Arts | Results Presentation Deck | 17 slides · Electronic Arts
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
16
Includes two separate tables: one by platform (Console, PC, Mobile) and one by product type (Full game, Live services).Electronic Arts | Results Presentation Deck | 17 slides · Electronic Arts
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
09
Scientific diagram illustrating the mechanism of antigen presentation and T cell maturation.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
10
The slide uses a biological diagram to explain the 'problem' of immune evasion in cancer therapy.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
12
The slide uses a process flow diagram to illustrate the 8-step manufacturing timeline.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
18
The table shows 0/3 incidence of metastasis/ascites in the RENB-DC11 group compared to high incidence in control groups.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
20
N=2-3 sample size indicated at bottom left.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
22
The slide uses immunohistochemistry (brown staining) to visualize CD4+ T-cells, quantified in the bar chart.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
23
The slide uses immunohistochemistry images and a corresponding bar chart to demonstrate efficacy.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
25
The slide outlines a clinical development plan with specific milestones for 2025 and 2026, focusing on safety and efficacy cohorts.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
03
The slide uses a hub-and-spoke diagram to connect the company brand to three core pillars: team, portfolio, and financials.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · SetupLoop · Cost Of Inaction1 hit
09
The slide uses a KINOMEscan visualization to show selectivity.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Complication1 hit
11
The slide combines a biological pathway diagram with a clinical trial summary table to demonstrate clinical validation.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
12
The slide uses a side-by-side comparison of two market segments, each with a big number metric and supporting clinical/regulatory context.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
13
Includes a biological diagram illustrating the RAS protein state transition and mutation impact.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
14
The chart shows lower IC50 values for the Q61X mutation group, suggesting higher sensitivity to the drug.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
15
Waterfall plots showing best percentage change from baseline for two distinct patient cohorts.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
16
Includes a Kaplan-Meier survival curve comparing existing standard-of-care options.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
17
The slide uses a 'before-after' visual comparison to demonstrate clinical efficacy.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
18
The slide highlights US FDA Fast Track designation and superior PFS performance.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
19
The chart is a mirrored bar chart (diverging bar chart) showing AE frequency by grade.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
24
The chart is a Kaplan-Meier survival curve comparing a control arm to an experimental arm (EC).Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Solution1 hit
25
Shows efficacy data for ERAS-007 in combination with Encorafenib and Cetuximab.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Solution1 hit
29
The slide uses a stacked bar chart to show mutation incidence and a comparison table to highlight clinical trial failures in GBM compared to other indications.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Solution1 hit
31
The slide uses western blot data to demonstrate potency and a table to demonstrate pharmacokinetic superiority in mouse models.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Market Sizing1 hit
32
The chart is a Kaplan-Meier survival plot comparing three treatment groups.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Market Sizing1 hit
34
Erasca | Investor Presentation Deck | 41 slidesErasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Market Sizing1 hit